BriaCell Therapeutics Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1610820
Sentiment: neutral
Topics: filing, corporate-update, financials
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on 12/29/25. Check for Reg FD and financials.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on December 29, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides important updates and disclosures for investors regarding BriaCell Therapeutics Corp.'s regulatory compliance and financial status.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- December 29, 2025 (date) — Date of earliest event reported
- June 13, 2014 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for BriaCell Therapeutics Corp., covering Regulation FD Disclosures and Financial Statements and Exhibits, with the earliest event reported on December 29, 2025.
When was BriaCell Therapeutics Corp. previously known by another name?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp., with the date of the name change being June 13, 2014.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia, Canada.
What is BriaCell Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
BriaCell Therapeutics Corp.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for BriaCell Therapeutics Corp.?
The principal executive office address for BriaCell Therapeutics Corp. is Suite 300 - 235 15th Street West, Vancouver, BC V7T 2X1.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-29 16:05:49
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 265KB
- ex99-2.htm (EX-99.2) — 302KB
- ex99-2_001.jpg (GRAPHIC) — 20KB
- ex99-2_002.jpg (GRAPHIC) — 27KB
- ex99-2_003.jpg (GRAPHIC) — 23KB
- ex99-2_004.jpg (GRAPHIC) — 31KB
- ex99-2_005.jpg (GRAPHIC) — 20KB
- ex99-2_006.jpg (GRAPHIC) — 17KB
- ex99-2_007.jpg (GRAPHIC) — 26KB
- 0001493152-25-029363.txt ( ) — 1120KB
- bctx-20251229.xsd (EX-101.SCH) — 4KB
- bctx-20251229_def.xml (EX-101.DEF) — 26KB
- bctx-20251229_lab.xml (EX-101.LAB) — 36KB
- bctx-20251229_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams December 29, 2025 William V. Williams President and Chief Executive Officer